Corvus Pharmaceuticals Inc (CRVS) - Total Assets
Based on the latest financial reports, Corvus Pharmaceuticals Inc (CRVS) holds total assets worth $253.19 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See CRVS equity financing ratio to measure how much of total assets are equity-financed.
Corvus Pharmaceuticals Inc - Total Assets Trend (2014–2025)
This chart illustrates how Corvus Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Explore CRVS long-term investment intensity to see how much of total assets are deployed in long-term investments.
Corvus Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Corvus Pharmaceuticals Inc's total assets of $253.19 Million consist of 81.9% current assets and 18.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 6.4% |
| Accounts Receivable | $374.00K | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Corvus Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CRVS market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Corvus Pharmaceuticals Inc's current assets represent 81.9% of total assets in 2025, a decrease from 100.0% in 2014.
- Cash Position: Cash and equivalents constituted 6.4% of total assets in 2025, down from 99.9% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
Corvus Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Corvus Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Corvus Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 19.81 | 4.90 | 5.59 |
| Quick Ratio | 19.81 | 4.90 | 5.39 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $227.84 Million | $36.21 Million | $56.76 Million |
Corvus Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Corvus Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.10 |
| Latest Market Cap to Assets Ratio | 13.18 |
| Asset Growth Rate (YoY) | 3.2% |
| Total Assets | $71.12 Million |
| Market Capitalization | $937.61 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Corvus Pharmaceuticals Inc's assets at a significant premium (13.18x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Corvus Pharmaceuticals Inc's assets grew by 3.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Corvus Pharmaceuticals Inc (2014–2025)
The table below shows the annual total assets of Corvus Pharmaceuticals Inc from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $71.12 Million | +3.21% |
| 2024-12-31 | $68.91 Million | +51.27% |
| 2023-12-31 | $45.55 Million | -33.25% |
| 2022-12-31 | $68.24 Million | -37.65% |
| 2021-12-31 | $109.45 Million | +27.97% |
| 2020-12-31 | $85.53 Million | +2.25% |
| 2019-12-31 | $83.65 Million | -29.25% |
| 2018-12-31 | $118.23 Million | +24.75% |
| 2017-12-31 | $94.78 Million | -32.38% |
| 2016-12-31 | $140.15 Million | +42.34% |
| 2015-12-31 | $98.46 Million | +685.85% |
| 2014-12-31 | $12.53 Million | -- |
About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-cen… Read more